Anatara Lifesciences (ASX:ANR) obtained a standard patent for its gastrointestinal re-programming product, known as GaRP, in Hong Kong, according to a Monday filing with the Australian bourse.
The patent is valid for 20 years from Oct. 9, 2020, and follows a similar grant from the European Union in September 2024, and in Australia on Jan. 28 of this year.
Anatara Lifesciences recently concluded its trial for GaRP as treatment for debilitating symptoms of digestive disorders, including irritable bowel syndrome (IBS), per the filing.
Anatara Lifesciences' shares fell 8% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。